Research programme: ISS-cedar pollen conjugates - Dynavax/RIKEN
Latest Information Update: 06 Aug 2007
At a glance
- Originator Dynavax Technologies; RIKEN
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 18 Oct 2004 Preclinical trials in Seasonal allergic rhinitis in Japan (Injection)
- 18 Oct 2004 Preclinical trials in Seasonal allergic rhinitis in USA (Injection)